India's Drug Regulator Aims to Boost Efficiency with AI and Streamlined Processes

India's Drug Regulator Unveils Plans for Efficiency Boost

India's Central Drugs Standard Control Organisation (CDSCO) has announced ambitious plans to revolutionize its regulatory processes, aiming to enhance efficiency and foster growth in the pharmaceutical sector. Rajeev Raghuvanshi, the Drugs Controller General, outlined the regulator's vision for a more streamlined and technologically advanced approach to oversight 1

1

Streamlining Processes and Timelines

The CDSCO has already taken significant steps to reduce bureaucratic hurdles:

• Processing time for drug test licenses has been halved to 45 days
• Some studies now require only an intimation, eliminating the need for prior licensing
• Export certifications are now cleared in under seven days

These changes reflect the regulator's commitment to "increase our efficiency, cutting down on regulations so that we create more and more resources within our system," as stated by Raghuvanshi 2

2

Source: Reuters

Exploring Artificial Intelligence

In a forward-thinking move, the CDSCO is exploring the integration of artificial intelligence into its regulatory framework. This technological leap aims to further boost efficiency and modernize the agency's operations. However, Raghuvanshi emphasized the need for caution, stating that the regulator is "examining how to avoid legal infringements" in the implementation of AI 1

1

Related Stories

AI Takes Center Stage at Pharmaceutical Conference, Overshadowing US Tariff Concerns

FDA and OpenAI Explore AI Integration for Accelerating Drug Evaluations

FDA Embraces AI to Accelerate Drug Approvals and Enhance Efficiency

Drugmakers deploy AI to accelerate clinical trials and slash regulatory submission timelines

Global Expansion and Trade Outlook

The Indian pharmaceutical industry is positioning itself for global expansion, despite uncertainties in the international trade landscape:

• The sector is exempt from U.S. President Donald Trump's tariffs of up to 50 percent
• U.S. sales of mainly generic medicines from India rose by 20% to approximately $10.5 billion in fiscal 2025
• The U.S. market accounts for over a third of India's drug exports

This growth trajectory underscores the importance of the regulator's efforts to streamline processes and enhance efficiency, as it directly impacts India's competitiveness in the global pharmaceutical market 2

2

Future Outlook

Raghuvanshi summarized the CDSCO's philosophy moving forward: "The way for the future is to make the regulation lighter and execution stronger." This approach signals a shift towards a more agile and responsive regulatory environment, which could significantly benefit both domestic and international stakeholders in the pharmaceutical industry 1

1

As India's drug regulator continues to evolve and adapt to the changing landscape of global pharmaceuticals, the industry watches closely to see how these changes will impact drug development, approval processes, and international trade in the coming years.